第 1 到 295 筆結果,共 295 筆。
公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 | |
---|---|---|---|---|---|---|---|
1 | 2020 | Withdrawal of Nucleos(t)ide Analogues in Hepatitis B e Antigen–Negative Patients: An Asian Perspective | TUNG-HUNG SU ; JIA-HORNG KAO | Clinical Liver Disease | 1 | 0 | |
2 | 2021 | What we have learned from COVID-19 pandemic? | Chen, Tony Hsiu Hsi ; JIA-HORNG KAO ; JIN-SHING CHEN ; YEN-HSUAN NI | Journal of the Formosan Medical Association = Taiwan yi zhi | 1 | 0 | |
3 | 2015 | What can we learn from hepatitis B virus clinical cohorts? | Lin C.-L.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Liver International | 11 | 10 | |
4 | 2007 | Viremia profiles in hepatitis B virus carrier children with spontaneous e antigen seroconversion: a case of déjà vu? | Lin C.-L.; JIA-HORNG KAO | Gastroenterology | 0 | 0 | |
5 | 2015 | Viral hepatitis: HBV cure-can we pin our hopes on immunotherapy? | HUNG-CHIH YANG ; JIA-HORNG KAO | Nature Reviews Gastroenterology and Hepatology | 28 | 22 | |
6 | 2010 | Use of statins and gallstone risk [1] | Hsu C.-S.; JIA-HORNG KAO | JAMA - Journal of the American Medical Association | 4 | 3 | |
7 | 2017 | Urgency to treat patients with chronic hepatitis C in Asia | JIA-HORNG KAO ; Ahn S.H.; Chien R.-N.; Cho M.; Chuang W.-L.; Jeong S.-H.; CHEN-HUA LIU ; Paik S.-W. | Journal of Gastroenterology and Hepatology (Australia) | 19 | 18 | |
8 | 2017 | An update on non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in Asia | Hsu C.S.; JIA-HORNG KAO | Expert Review of Gastroenterology and Hepatology | 11 | 11 | |
9 | 2017 | Unmet Needs in Clinical and Basic Hepatitis B Virus Research | TUNG-HUNG SU ; JIA-HORNG KAO | Journal of Infectious Diseases | 19 | 17 | |
10 | 2008 | Universal Hepatitis B Vaccination: Killing 2 Birds with 1 Stone | JIA-HORNG KAO ; DING-SHINN CHEN | American Journal of Medicine | 12 | 12 | |
11 | 2011 | Uncovered issues in the overview of nonalcoholic steatohepatitis | Wang C.-C.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
12 | 2014 | Triple therapy for hepatitis C virus infection in patients receiving hemodialysis | CHEN-HUA LIU ; JIA-HORNG KAO | Annals of Internal Medicine | 1 | 1 | |
13 | 2022 | Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry | Wong Y.J.; Kumar R.; Kumar R.; Tan J.; CHEN-HUA LIU ; Hui V.W.-K.; Tan S.S.; JIA-HORNG KAO ; Wong G.L.-H.; Thurairajah P.H. | Journal of Gastroenterology and Hepatology (Australia) | 4 | 2 | |
14 | 2017 | Treatment of de novo hepatitis C virus-related fibrosing cholestatic hepatitis after orthotopic heart transplantation by ledipasvir and sofosbuvir | CHEN-HUA LIU ; YIH-SHARNG CHEN ; SHOEI-SHEN WANG ; JIA-HORNG KAO | Journal of the Formosan Medical Association | 4 | 6 | |
15 | 2015 | Treating Immune-tolerant Hepatitis B | TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of viral hepatitis | 39 | 32 | |
16 | 2020 | Towards elimination of viral hepatitis in Taiwan by 2025: In memory of Professor Ding-Shinn Chen (1943-2020) | HUNG-CHIH YANG ; JIA-HORNG KAO | Journal of the Formosan Medical Association | 3 | 2 | |
17 | 2007 | To genotype or not to genotype: Toward an optimal tailoring of treatment of chronic hepatitis B [3] | Lin C.-.; JIA-HORNG KAO | Clinical Infectious Diseases | 2 | 3 | |
18 | 2005 | Therapeutic implications of hepatitis B virus genotypes | CHUN-JEN LIU ; JIA-HORNG KAO ; DING-SHINN CHEN | Liver International | 108 | 82 | |
19 | 2017 | Telbivudine therapy for chronic hepatitis B: A journey to identify super-responders and to optimize treatment using the roadmap model | JIA-HORNG KAO ; Asselah T.; Dou X.-G.; Hamed K. | Journal of Gastroenterology and Hepatology (Australia) | 5 | 6 | |
20 | 2009 | Telaprevir for chronic HCV infection | JIA-HORNG KAO | New England Journal of Medicine | 3 | 3 | |
21 | 2023 | TASL, TADE, and DAROC consensus for the screening and management of hepatitis C in patients with diabetes | Yu, Ming-Lung; CHIH-YUAN WANG ; Lee, Mei-Hsuan; Ou, Horng-Yih; Cheng, Pin-Nan; Tu, Shih-Te; Huang, Jee-Fu; Chen, Jung-Fu; Hu, Tsung-Hui; Hsu, Chih-Cheng; JIA-HORNG KAO ; Chen, Chien-Jen; Lin, Han-Chieh; Huang, Chien-Ning | Journal of the Formosan Medical Association = Taiwan yi zhi | 2 | 2 | |
22 | 2022 | Systemic therapy for hepatocellular carcinoma: New agents and therapeutic hierarchy | TUNG-HUNG SU ; SHIH-JER HSU ; JIA-HORNG KAO | Journal of the Formosan Medical Association = Taiwan yi zhi | 0 | 0 | |
23 | 2015 | Systematic review: Impact of interferon-based therapy on HCV-related hepatocellular carcinoma | Hsu C.-S.; Chao Y.-C.; Lin H.H.; DING-SHINN CHEN ; JIA-HORNG KAO | Scientific Reports | 56 | 46 | |
24 | 2020 | Systematic review: chronic viral hepatitis and metabolic derangement | Wang C.-C.; Cheng P.-N.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 70 | 54 | |
25 | 2017 | Surveillance of hepatocellular carcinoma by magnetic resonance imaging with liver-specific contrast | TUNG-HUNG SU ; JIA-HORNG KAO | JAMA Oncology | 3 | 2 | |
26 | 2005 | Subgenotypes of hepatitis B virus genotype C in Taiwan [3] (multiple letters) | CHUN-JEN LIU ; JIA-HORNG KAO ; Chan H.L.-Y. | Journal of Infectious Diseases | 4 | 4 | |
27 | 2022 | Strategies for hepatitis C virus treatment failure | SHANG-CHIN HUANG ; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
28 | 1993 | Sexual transmission of HCV | JIA-HORNG KAO ; PEI-JER CHEN ; Lei M.-Y.; Wang T.-H.; Chen D.-S.; Benezra J. | The Lancet | 11 | 15 | |
29 | 2007 | Sequential combination therapy for chronic hepatitis B: More challenges to be tackled [7] | TAI-CHUNG TSENG ; CHUN-JEN LIU ; JIA-HORNG KAO | American Journal of Gastroenterology | 1 | 1 | |
30 | 2018 | Sarcopenia and chronic liver diseases | Hsu C.-S.; JIA-HORNG KAO | Expert Review of Gastroenterology and Hepatology | 74 | 61 | |
31 | 2010 | Role of Viral Factors in Modifying Weight-Related Effects on Disease Progression of Chronic Hepatitis C Patients | Hsu C.; JIA-HORNG KAO | Gastroenterology | 0 | 0 | |
32 | 2019 | The Role of Hepatitis B Surface Antigen in Nucleos(t)ide Analogue Cessation Among Asian Chronic Hepatitis B Patients: Friend or Foe? | Wang C.-C.; JIA-HORNG KAO | Hepatology | 2 | 1 | |
33 | 2014 | Risk stratification of HBV infection in Asia-Pacific region | JIA-HORNG KAO | Clinical and molecular hepatology | 20 | 0 | |
34 | 2020 | Risk of hepatocellular carcinoma development after hepatitis C virus eradicated by direct-acting antivirals: Fact or fiction? | SHIH-JER HSU ; Yang S.-S.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 16 | 14 | |
35 | 2010 | Rifaximin treatment in hepatic encephalopathy [1] | Wang C.-C.; JIA-HORNG KAO | New England Journal of Medicine | 13 | 5 | |
36 | 2015 | A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan | Bennett H.; Waser N.; Johnston K.; JIA-HORNG KAO ; Lim Y.-S.; Duan Z.-P.; Lee Y.-J.; Wei L.; Chen C.-J.; Sievert W.; Yuan Y.; Li H. | Hepatology International | 80 | 73 | |
37 | 2018 | Review article: the prevention of hepatitis B-related hepatocellular carcinoma | Lin C.-L.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 40 | 35 | |
38 | 2022 | Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data | Lim Y.-S.; Seto W.-K.; Kurosaki M.; Fung S.; JIA-HORNG KAO ; Hou J.; Gordon S.C.; Flaherty J.F.; Yee L.J.; Zhao Y.; Agarwal K.; Lampertico P. | Alimentary Pharmacology and Therapeutics | 12 | 11 | |
39 | 2016 | Review article: novel therapies for hepatitis B virus cure – advances and perspectives | Lin C.-L.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 45 | 39 | |
40 | 2023 | Response to Singh et al | TAI-CHUNG TSENG ; Hosaka, Tetsuya; JIA-HORNG KAO | American Journal of Gastroenterology | 0 | 0 | |
41 | 2021 | Response to letter to the editor “The impact of cytokine change after hepatitis C virus clearance by direct antiviral agents on the risk of hepatocellular carcinoma” | Cheng Y.-M.; Tzeng I.-S.; JIA-HORNG KAO ; Wang C.-C. | Journal of the Formosan Medical Association | 0 | 0 | |
42 | 2021 | Response to letter to the editor “Factors predicting outcomes of hepatitis B-related cirrhosis patients with long-term antiviral therapy” | Lin C.-L.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
43 | 2017 | Response to Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients | TUNG-HUNG SU ; JIA-HORNG KAO | Liver International | 2 | 2 | |
44 | 2022 | Response to "Iodized Oil CT-Guided Radiofrequency Ablation for Hepatocellular Carcinoma Within Milan Criteria" | CHIH-HORNG WU ; JIA-HORNG KAO | Hepatology international | 0 | 0 | |
45 | 2021 | Reply to: “Sofosbuvir and the risk of kidney dysfunction” | CHEN-HUA LIU ; JIA-HORNG KAO | Journal of Hepatology | 0 | 0 | |
46 | 2015 | Reply to: Modulation of Toll-like receptor 9 expression on monocytes of viral hepatitis patients | YI-WEN HUANG ; Yang S.-S.; JIA-HORNG KAO | Antiviral Therapy | 0 | 0 | |
47 | 2021 | Reply to “Tacrolimus concentrations were not affected by glecaprevir/pibrentasvir treatment for hepatitis C virus infection in an adult living donor liver transplant recipient with uremia” | Yu M.-L.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
48 | 2024 | Reply to “Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy” | Lin, Meng-Ju; TUNG-HUNG SU ; JIA-HORNG KAO | Journal of the Formosan Medical Association = Taiwan yi zhi | 0 | 0 | |
49 | 1995 | Reply To the Editor | Lin H.-H.; JIA-HORNG KAO ; PEI-JER CHEN ; DING-SHINN CHEN | The Journal of Pediatrics | 0 | 0 | |
50 | 2020 | Reply to letter to the editor: Successful eradication of HCV by short-course DAAs in HCV positive donor to HCV-Negative recipient during Haplo-HSCT | Huang C.-F.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
51 | 2011 | Reply to Guedj et al.: Early transient increase of hepatitis C virus viral load in genotype 1 and 2 infections, and the use of mathematical modeling | Hsu C.-S.; Chen H.-C.; Jeng J.; JIA-HORNG KAO ; DING-SHINN CHEN | Proceedings of the National Academy of Sciences of the United States of America | 0 | 0 | |
52 | 2007 | Reply [2] | Lin C.-L.; CHUN-JEN LIU ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
53 | 2024 | Reply | SHANG-CHIN HUANG ; TUNG-HUNG SU ; JIA-HORNG KAO | Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association | |||
54 | 2023 | Reply | TAI-CHUNG TSENG ; JIA-HORNG KAO | Gastroenterology | 0 | 0 | |
55 | 2016 | Reply | Su T.-H.; CHI-LING CHEN ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
56 | 2002 | Recent updates in hepatitis vaccination and the prevention of hepatocellular carcinoma | JIA-HORNG KAO ; DING-SHINN CHEN | International Journal of Cancer | 13 | 10 | |
57 | 2002 | Recent research progress in hepatocellular carcinoma | JIA-HORNG KAO ; DING-SHINN CHEN | Journal of the Formosan Medical Association | 20 | 21 | |
58 | 2011 | Recent advances in the treatment of chronic hepatitis B | Lin C.-L.; JIA-HORNG KAO | Expert Opinion on Pharmacotherapy | 26 | 26 | |
59 | 2010 | Recent advances in clinical application of gut hormones | PING-HUEI TSENG ; MING-SHIANG WU ; JIA-HORNG KAO | Journal of the Formosan Medical Association | 4 | 4 | |
60 | 2009 | Reactivation of hepatitis B virus in an inactive hepatitis B carrier with glucocorticoid pulse therapy | TAI-CHUNG TSENG ; CHUN-JEN LIU ; SONG-CHOU HSIEH ; PEI-JER CHEN ; Lai M.-Y.; DING-SHINN CHEN ; JIA-HORNG KAO | Digestive and Liver Disease | 3 | 3 | |
61 | 2013 | Quantitative hepatitis B core antibody level may help predict treatment response in chronic hepatitis B patients | Yuan Q.; Song L.-W.; CHUN-JEN LIU ; Li Z.; Liu P.-G.; Huang C.-H.; Yan Y.; Ge S.-X.; Wang Y.-B.; Peng C.-Y.; Zhang J.; JIA-HORNG KAO ; DING-SHINN CHEN ; PEI-JER CHEN ; Xia N.-S. | Gut | 67 | 63 | |
62 | 2019 | Quantification of Hepatitis B Core Antibody Helps Predict Clinical Relapse After Cessation of Nucleos(t)ide Analogues in Chronic Hepatitis B Patients: More Needs to Be Done | Hsu Y.-C.; Tseng C.-H.; JIA-HORNG KAO | Clinical Gastroenterology and Hepatology | 5 | 2 | |
63 | 2019 | Quantification of HBV core antibodies may help revisit infectious occult hepatitis B virus | HUNG-CHIH YANG ; JIA-HORNG KAO | Gut | 4 | 2 | |
64 | 2018 | Prevention of mother-to-child transmission: the key of hepatitis B virus elimination | Lin C.-L.; JIA-HORNG KAO | Hepatology International | 5 | 5 | |
65 | 2009 | Prevention of hepatocellular carcinoma in hepatitis B virus infection | Lim S.G.; Mohammed R.; Yuen M.-F.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 63 | 61 | |
66 | 2021 | Prevention of hepatitis b virus-related hepatocellular carcinoma | Lin C.-L.; JIA-HORNG KAO | Hepatoma Research | 15 | 15 | |
67 | 2018 | Preface | JIA-HORNG KAO ; DING-SHINN CHEN | Hepatitis B Virus and Liver Disease | 0 | 0 | |
68 | 2022 | Pooling data to assess risks and benefits of discontinuing nucleos(t)ide analogs in patients with chronic hepatitis B: challenges and opportunities | Hsu, Yao-Chun; Tseng, Cheng-Hao; TUNG-HUNG SU ; JIA-HORNG KAO ; Nguyen, Mindie H | Gut | 3 | 2 | |
69 | 2016 | Perspectives on dual hepatitis B and C infection in Taiwan | CHUN-JEN LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of the Formosan Medical Association | 13 | 12 | |
70 | 2015 | Perspectives and control of hepatitis B virus infection in Taiwan | Lin C.-L.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 64 | 62 | |
71 | 2014 | Persistence of hepatitis B virus covalently closed circular DNA in hepatocytes: Molecular mechanisms and clinical significance | HUNG-CHIH YANG ; JIA-HORNG KAO | Emerging Microbes and Infections | 102 | 104 | |
72 | 2006 | Pegylated interferons for the treatment of chronic hepatitis B. | CHUN-JEN LIU ; JIA-HORNG KAO | Recent patents on anti-infective drug discovery | 5 | 0 | |
73 | 2009 | Pegylated interferon α-2a plus low-dose ribavirin for the retreatment of dialysis chronic hepatitis C patients who relapsed from prior interferon monotherapy | CHEN-HUA LIU ; Liang C.-C.; CHUN-JEN LIU ; Tsai H.-B.; Hung P.-H.; SHIH-JER HSU ; Chen S.-L.; JOU-WEI LIN ; Lai M.-Y.; Chen J.-H.; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Gut | 26 | 23 | |
74 | 2009 | Peginterferon alfa-2b or alfa-2a with ribavirin for hepatitis C | Hsu C.-S.; JIA-HORNG KAO | New England Journal of Medicine | 4 | 2 | |
75 | 2007 | Peginterferon alfa-2a and ribavirin for 16 or 24 weeks in HCV [6] | CHEN-HUA LIU ; DING-SHINN CHEN ; JIA-HORNG KAO | New England Journal of Medicine | 1 | 1 | |
76 | 2002 | Paratyphoid hepatitis: An emerging clinical entity [5] | PO-REN HSUEH ; JIA-HORNG KAO ; YEE-CHUN CHEN ; PAN-CHYR YANG ; KWEN-TAY LUH ; Wang T.-K.; Lin S.-F. | American Journal of Medicine | 7 | 5 | |
77 | 2022 | Pan-genotypic direct-acting antivirals for patients with hepatitis C virus infection and chronic kidney disease stage 4 or 5 | CHEN-HUA LIU ; JIA-HORNG KAO | Hepatology International | 7 | 8 | |
78 | 2010 | Outcomes of HCV treatment: Who does well and who does not? | Hsu C.-S.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 1 | 1 | |
79 | 2010 | Optimal management of hepatocellular carcinoma: Challenges and opportunities | Lin C.-L.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 8 | 5 | |
80 | 2019 | Nucleos(t)ide analogues in patients with chronic hepatitis B: To stop or not to stop? | JIA-HORNG KAO ; Berg T. | Gut | 6 | 3 | |
81 | 2012 | Non-alcoholic fatty liver disease: An emerging liver disease in Taiwan | Hsu C.-S.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 34 | 30 | |
82 | 2017 | NOhep: Toward Global Control of Hepatitis B Virus Infection - An Introduction | CHUN-JEN LIU ; JIA-HORNG KAO | Journal of Infectious Diseases | 4 | 4 | |
83 | 2016 | New perspectives of biomarkers for the management of chronic hepatitis B | Lin C.-L.; JIA-HORNG KAO | Clinical and Molecular Hepatology | 48 | 0 | |
84 | 2023 | New Approaches to Chronic Hepatitis B | TAI-CHUNG TSENG ; JIA-HORNG KAO ; Dusheiko, Geoffrey; Agarwal, Kosh; Maini, Mala K. | New England Journal of Medicine | 1 | 0 | |
85 | 2017 | Natural history of acute and chronic hepatitis B: The role of HBV genotypes and mutants | Lin C.-L.; JIA-HORNG KAO | Best Practice and Research: Clinical Gastroenterology | 133 | 115 | |
86 | 2014 | Nanomedicines in the treatment of hepatitis C virus infection in Asian patients: Optimizing use of peginterferon alfa | CHEN-HUA LIU ; JIA-HORNG KAO | International Journal of Nanomedicine | 33 | 34 | |
87 | 2001 | Mother-to-child HCV transmission [1] (multiple letters) | Semprini A.E.; Savasi V.; Hollander L.; Tanzi E.; Fiore S.; Newell M.-L.; Pembrey L.; Zanetti A.; Coll O.; Numazaki K.; Fujikawa T.; Chiba S.; Hari P.; Prasad C.G.K.; Lankipalli R.; HO-HSIUNG LIN ; JIA-HORNG KAO ; DING-SHINN CHEN ; Gibb D.M.; Dunn D.T.; Goodall R.L. | Lancet | 7 | 3 | |
88 | 2017 | More viral mutants, less HBsAg clearance? One size may not fit all | TAI-CHUNG TSENG ; HUNG-CHIH YANG ; JIA-HORNG KAO | Gut | 2 | 1 | |
89 | 1999 | Molecular methods of measurement of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus infection: Implications for occupational health practice | JIA-HORNG KAO ; Heptonstall J.; DING-SHINN CHEN | Occupational and Environmental Medicine | 11 | 9 | |
90 | 2014 | Molecular mechanism and treatment of viral hepatitis-related liver fibrosis | TUNG-HUNG SU ; JIA-HORNG KAO ; CHUN-JEN LIU | International Journal of Molecular Sciences | 57 | 52 | |
91 | 2003 | Molecular Assays for Hepatitis B Virus Infection [1] | CHUN-JEN LIU ; JIA-HORNG KAO ; DING-SHINN CHEN | Hepatology | 5 | 5 | |
92 | 2006 | Mixed hepatitis B virus genotype infections: The more, the worse? [3] | CHUN-JEN LIU ; JIA-HORNG KAO ; DING-SHINN CHEN | Hepatology | 8 | 5 | |
93 | 2010 | Metformin improves sustained virologic response in difficult-to-cure hepatitis c: More questions than answers | Wang C.-C.; JIA-HORNG KAO | Hepatology | 3 | 3 | |
94 | 2010 | Metabolic syndrome on top of chronic hepatitis B: the more, the worse? | LI-CHUN CHANG ; Chung, Chen-Shuan; CHUN-JEN LIU ; JIA-HORNG KAO | Gut | 1 | 1 | |
95 | 2022 | Metabolic dysfunction-associated fatty liver disease and chronic hepatitis B | SHANG-CHIN HUANG ; JIA-HORNG KAO | Journal of the Formosan Medical Association | 7 | 6 | |
96 | 2005 | Medical treatment of fish bone-related liver abscess [5] | Yang C.-Y.; JIA-HORNG KAO ; KAO-LANG LIU ; SHYH-JYE CHEN | Clinical Infectious Diseases | 15 | 12 | |
97 | 1996 | Mechanism of vertical transmission of hepatitis G [6] | HO-HSIUNG LIN ; IA-HORNG KAO ; PEI-JER CHEN ; DING-SHINN CHEN | Lancet | 40 | 27 | |
98 | 2016 | Management of hepatitis C patients with decompensated liver disease | Hsu C.-S.; JIA-HORNG KAO | Expert Review of Gastroenterology and Hepatology | 5 | 4 | |
99 | 2016 | Looking into the crystal ball: biomarkers for outcomes of HBV infection | HUNG-CHIH YANG ; JIA-HORNG KAO | Hepatology International | 10 | 10 | |
100 | 2022 | Looking Into the Crystal Ball: A Novel Biomarker for Outcomes of Patients With Chronic Hepatitis B Virus Infection | TAI-CHUNG TSENG ; Wu J.-W.; JIA-HORNG KAO | Hepatology Communications | 0 | 0 | |
101 | 2006 | Local ablation vs. resection for the treatment of hepatocellular carcinoma [1] | JIA-HORNG KAO ; DING-SHINN CHEN | Hepatology | 5 | 4 | |
102 | 2022 | Letter: vaccination for global control of hepatitis B—from prevention to elimination | Lin, Chih Lin; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 | |
103 | 2017 | Letter: the influence of direct acting agents for hepatitis C, on hepatitis B reactivation | Wang C.-C.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 | |
104 | 2020 | letter: hepatitis B virus infection and risk of multiple myeloma—a meta-analysis of cohort studies. Authors' reply | TUNG-HUNG SU ; CHI-LING CHEN ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 | |
105 | 2022 | Letter: hepatic steatosis and fibrosis in chronic hepatitis B—the chicken-and-egg conundrum | SHANG-CHIN HUANG ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 2 | 2 | |
106 | 2017 | letter: HBsAg kinetics-guided interferon therapy for chronic hepatitis D | Kao C.-N.; TUNG-HUNG SU ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 1 | 1 | |
107 | 2021 | Letter: elevated HBV DNA predicts poor survival in hepatocellular carcinoma after hepatic resection—authors' reply | TAI-CHUNG TSENG ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 1 | 1 | |
108 | 2020 | Letter: elevated aspartate aminotransferase and aspartate aminotransferase to alanine aminotransferase ratio predicts poor survival in hepatocellular carcinoma after resection—Authors' reply | Wai-Sun Wong V.; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 1 | 1 | |
109 | 2019 | Letter: contraindicated drug-drug interactions before and after initiation of direct-acting anti-viral agents in chronic hepatitis C patients in Taiwan. Authors’ reply | CHEN-HUA LIU ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 | |
110 | 2022 | Letter to the editor: New kid in the playground: HBcrAg and risk of HCC | Wu J.-W.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
111 | 2023 | Letter to the Editor: Learning more about the safety of atezolizumab plus bevacizumab in patients with hepatocellular carcinoma | CHIA-CHI WANG ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
112 | 2023 | Letter to the Editor: Hepatic steatosis and glycemic burden in chronic hepatitis B | SHANG-CHIN HUANG ; JIA-HORNG KAO | Hepatology (Baltimore, Md.) | 1 | 1 | |
113 | 2010 | Letter to the editor | Wang C.-C.; JIA-HORNG KAO | New England Journal of Medicine | 2 | ||
114 | 1995 | Letter | HO-HSIUNG LIN ; JIA-HORNG KAO ; PEI-JER CHEN ; DING-SHINN CHEN | The Journal of Pediatrics | |||
115 | 2021 | Last Mile to Microelimination of Hepatitis C Virus Infection Among People Living With Human Immunodeficiency Virus | CHEN-HUA LIU ; JIA-HORNG KAO | Clinical infectious diseases : an official publication of the Infectious Diseases Society of America | 7 | 6 | |
116 | 2019 | Large and middle hepatitis B surface antigen: The lower the better? | Lin H.-H.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Gut | 1 | 1 | |
117 | 2006 | Kinetics of Hepatitis B Virus Reactivation After Chemotherapy: More Questions Than Answers | CHUN-JEN LIU ; JIA-HORNG KAO ; DING-SHINN CHEN | Gastroenterology | 7 | 7 | |
118 | 2007 | Intrafamilial transmission of hepatitis B virus infection [3] | Lin C.-L.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 3 | 2 | |
119 | 2011 | Interleukin-28B genetic variations and response to interferon-based therapy: Asian perspectives | CHEN-HUA LIU ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 6 | 6 | |
120 | 2007 | Interferon-based therapy for dialysis patients with chronic hepatitis C: Progress and challenges | CHEN-HUA LIU ; CHUN-JEN LIU ; JIA-HORNG KAO | Nephrology | 2 | 7 | |
121 | 2008 | Insulin resistance, adipocytokines, and hepatitis C virus infection: A missing link? | Hsu C.-S.; JIA-HORNG KAO | Hepatology | 0 | 0 | |
122 | 2015 | Improving clinical outcomes of chronic hepatitis B virus infection | TUNG-HUNG SU ; JIA-HORNG KAO | Expert review of Gastroenterology and Hepatology | 26 | 23 | |
123 | 2010 | Implications of hepatitis B virus genomic variations on treatment outcomes | TAI-CHUNG TSENG ; CHUN-JEN LIU ; JIA-HORNG KAO | Current Pharmacogenomics and Personalized Medicine | 5 | 0 | |
124 | 2013 | IL28B genotype on HCV infection in Asia | CHEN-HUA LIU ; JIA-HORNG KAO | Current Hepatitis Reports | 3 | 0 | |
125 | 2007 | Hypercholesterolemia in primary biliary cirrhosis [10] | TA-CHEN SU ; HWANG, JUEY-JEN ; JIA-HORNG KAO | New England Journal of Medicine | 20 | 20 | |
126 | 2016 | How have the recent advances in antiviral therapy impacted the management of virus-related hepatocellular carcinoma? | Wang C.-C.; JIA-HORNG KAO | Expert Opinion on Pharmacotherapy | 13 | 11 | |
127 | 2021 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
128 | 2019 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
129 | 2019 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
130 | 2019 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
131 | 2019 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
132 | 2023 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
133 | 2023 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
134 | 2023 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
135 | 2023 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
136 | 2022 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
137 | 2022 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
138 | 2022 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
139 | 2023 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
140 | 2023 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
141 | 2018 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
142 | 2021 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
143 | 2021 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
144 | 2020 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
145 | 2019 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
146 | 2019 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
147 | 2018 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
148 | 2018 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
149 | 2021 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
150 | 2018 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
151 | 2020 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
152 | 2018 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
153 | 2018 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
154 | 2020 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
155 | 2019 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
156 | 2022 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
157 | 2022 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
158 | 2020 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
159 | 2021 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
160 | 2021 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
161 | 2023 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
162 | 2023 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
163 | 2021 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
164 | 2018 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
165 | 2019 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
166 | 2021 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
167 | 2020 | HIGHLIGHTS | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
168 | 2020 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
169 | 2022 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
170 | 2018 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
171 | 2022 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
172 | 2022 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
173 | 2022 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
174 | 2022 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
175 | 2024 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
176 | 2022 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
177 | 2020 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
178 | 2018 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 1 | |
179 | 2018 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
180 | 2018 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
181 | 2018 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
182 | 2019 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
183 | 2019 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
184 | 2019 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
185 | 2021 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
186 | 2020 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
187 | 2020 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
188 | 2020 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
189 | 2020 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
190 | 2023 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
191 | 2023 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
192 | 2023 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
193 | 2023 | Highlights | JIA-HORNG KAO | Journal of the Formosan Medical Association | |||
194 | 2004 | Heterogeneity of hereditary persistence of alpha-fetoprotein [1] (multiple letters) | Shiou-Hwei Yeh ; JIA-HORNG KAO ; PEI-JER CHEN ; Perlemuter G.; Alj Y.; Buffet C.; Guiochon-Mantel A. | Gastroenterology | 0 | 5 | |
195 | 2016 | Hepatocellular carcinoma recurrence after interferon-free direct acting antiviral treatment for chronic hepatitis C virus infection: Fact or fiction? | CHEN-HUA LIU ; JIA-HORNG KAO | Translational Cancer Research | 2 | 3 | |
196 | 2011 | Hepatitis during antituberculosis treatment | Wu L.-W.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
197 | 2023 | Hepatitis D Virus Infection | SHANG-CHIN HUANG ; JIA-HORNG KAO | The New England journal of medicine | |||
198 | 2023 | Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries | Razavi, Homie A.; Buti, Maria; Terrault, Norah A.; Zeuzem, Stefan; Yurdaydin, Cihan; Tanaka, Junko; Aghemo, Alessio; Akarca, Ulus S.; Al Masri, Nasser M.; Alalwan, Abduljaleel M.; Aleman, Soo; Alghamdi, Abdullah S.; Alghamdi, Saad; Al-Hamoudi, Waleed K.; Aljumah, Abdulrahman A.; Altraif, Ibrahim H.; Asselah, Tarik; Ben-Ari, Ziv; Berg, Thomas; Biondi, Mia J.; Blach, Sarah; Braga, Wornei S.M.; Brandão-Mello, Carlos E.; Brunetto, Maurizia R.; Cabezas, Joaquin; Cheinquer, Hugo; PEI-JER CHEN ; Cheon, Myeong Eun; Chuang, Wan Long; Coffin, Carla S.; Coppola, Nicola; Craxi, Antonio; Crespo, Javier; De Ledinghen, Victor; Duberg, Ann Sofi; Etzion, Ohad; Ferraz, Maria Lucia G.; Ferreira, Paulo R.A.; Forns, Xavier; Foster, Graham R.; Gaeta, Giovanni B.; Gamkrelidze, Ivane; García-Samaniego, Javier; Gheorghe, Liliana S.; Gholam, Pierre M.; Gish, Robert G.; Glenn, Jeffrey; Hercun, Julian; Hsu, Yao Chun; Hu, Ching Chih; Huang, Jee Fu; Janjua, Naveed; Jia, Jidong; Kåberg, Martin; Kaita, Kelly D.E.; Kamal, Habiba; JIA-HORNG KAO ; Kondili, Loreta A.; Lagging, Martin; Lázaro, Pablo; Lazarus, Jeffrey V.; Lee, Mei Hsuan; Lim, Young Suk; Marotta, Paul J.; Navas, Maria Cristina; Naveira, Marcelo C.M.; Orrego, Mauricio; Osiowy, Carla; Pan, Calvin Q.; Pessoa, Mário G.; Raimondo, Giovanni; Ramji, Alnoor; Razavi-Shearer, Devin M.; Razavi-Shearer, Kathryn; Ríos-Hincapié, Cielo Y.; Rodríguez, Manuel; Rosenberg, William M.C.; Roulot, Dominique M.; Ryder, Stephen D.; Safadi, Rifaat; Sanai, Faisal M.; Santantonio, Teresa A.; Sarrazin, Christoph; Shouval, Daniel; Tacke, Frank; Tergast, Tammo L.; Villalobos-Salcedo, Juan Miguel; Voeller, Alexis S.; Yang, Hwai I.; Yu, Ming Lung; Zuckerman, Eli | Journal of Hepatology | 11 | 3 | |
199 | 2010 | Hepatitis C virus infection, lipids, and coronary heart disease: A Pandora's box | Wang C.-C.; JIA-HORNG KAO | Hepatology | 4 | 5 | |
200 | 2016 | Hepatitis C virus infection in Taiwan: Past, present, and future | JIA-HORNG KAO | Journal of the Formosan Medical Association | 64 | 59 | |
201 | 1998 | Hepatitis C virus infection in Taiwan | JIA-HORNG KAO ; DING-SHINN CHEN | Chinese Journal of Public Health | 0 | ||
202 | 1998 | Hepatitis C virus infection and chronic active myocarditis [3] (multiple letters) | JIA-HORNG KAO ; HWANG, JUEY-JEN ; Okabe M.; Fukuda K.; Arakawa K.; Kikuchi M. | Circulation | 2 | 2 | |
203 | 2011 | Hepatitis C virus and lipid profiles: More questions than answers? | Hsu C.-S.; JIA-HORNG KAO | Hepatology International | 2 | 2 | |
204 | 2010 | Hepatitis C infection and metabolic syndrome. | Hsu C.S.; JIA-HORNG KAO | Journal of the Formosan Medical Association = Taiwan yi zhi | 11 | 9 | |
205 | 2020 | Hepatitis B: Immunization and Impact on Natural History and Cancer Incidence | Lin C.-L.; JIA-HORNG KAO | Gastroenterology clinics of North America | 15 | 14 | |
206 | 2018 | Hepatitis B: From control to cure | JIA-HORNG KAO | Journal of the Formosan Medical Association | 12 | 13 | |
207 | 2016 | Hepatitis B virus: New therapeutic perspectives | Lin C.-L.; HUNG-CHIH YANG ; JIA-HORNG KAO | Liver International | 45 | 36 | |
208 | 2020 | Hepatitis B virus: Advances in prevention, diagnosis, and therapy | Nguyen M.H.; Wong G.; Gane E.; JIA-HORNG KAO ; Dusheiko G. | Clinical Microbiology Reviews | 246 | 205 | |
209 | 2007 | Hepatitis B virus-related hepatocellular carcinoma: Epidemiology and pathogenic role of viral factors | CHUN-JEN LIU ; JIA-HORNG KAO | Journal of the Chinese Medical Association | 71 | 0 | |
210 | 2013 | Hepatitis B virus reactivation in patients receiving cancer chemotherapy: Natural history, pathogenesis, and management | CHUN-JEN LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | Hepatology International | 43 | 35 | |
211 | 2022 | Hepatitis B virus reactivation associated with new classes of immunosuppressants and immunomodulators: A systematic review, meta-analysis, and expert opinion | Papatheodoridis, George V.; Lekakis, Vasileios; Voulgaris, Thodoris; Lampertico, Pietro; Berg, Thomas; Chan, Henry L.Y.; JIA-HORNG KAO ; Terrault, Norah; Lok, Anna S.; Reddy, K. Rajender | Journal of Hepatology | 24 | 16 | |
212 | 2012 | Hepatitis B virus mutants associated with hepatitis b surface antigen loss: Chicken or egg? | TAI-CHUNG TSENG ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
213 | 2015 | Hepatitis B virus infection and metabolic syndrome: Fact or fiction? | Wang C.-C.; TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 67 | 64 | |
214 | 2017 | Hepatitis B virus infection and decreased risk of nonalcoholic fatty liver disease: A cohort study | Wang C.-C.; JIA-HORNG KAO | Hepatology | 14 | 12 | |
215 | 2004 | Hepatitis B Virus Genotypes and Core Promoter Variant [10] (multiple letters) | JIA-HORNG KAO ; DING-SHINN CHEN ; Lok A.S.F. | Gastroenterology | 0 | 1 | |
216 | 2007 | Hepatitis B virus genotype: What should the clinician know? | CHUN-JEN LIU ; JIA-HORNG KAO | Current Hepatitis Reports | 6 | 0 | |
217 | 2002 | Hepatitis B viral genotypes: Clinical relevance and molecular characteristics | JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 280 | 257 | |
218 | 2002 | Hepatitis B viral genotypes and lamivudine resistance [1] | JIA-HORNG KAO ; CHUN-JEN LIU ; DING-SHINN CHEN | Journal of Hepatology | 101 | 84 | |
219 | 2013 | Hepatitis B viral factors and treatment responses in chronic hepatitis B | Lin C.-L.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 34 | 32 | |
220 | 2008 | Hepatitis B viral factors and clinical outcomes of chronic hepatitis B | Lin C.-L.; JIA-HORNG KAO | Journal of Biomedical Science | 89 | 76 | |
221 | 2005 | Hepatitis B vaccination: To boost or not to boost? | JIA-HORNG KAO ; DING-SHINN CHEN | Lancet | 28 | 29 | |
222 | 2015 | Hepatitis B vaccination and prevention of hepatocellular carcinoma | JIA-HORNG KAO | Best Practice and Research: Clinical Gastroenterology | 80 | 64 | |
223 | 2011 | Hepatitis B surface antigen quantification: Why and how to use it in 2011 - A core group report | Chan H.L.-Y.; Thompson A.; Martinot-Peignoux M.; Piratvisuth T.; Cornberg M.; Brunetto M.R.; Tillmann H.L.; JIA-HORNG KAO ; Jia J.-D.; Wedemeyer H.; Locarnini S.; Janssen H.L.A.; Marcellin P. | Journal of Hepatology | 274 | 247 | |
224 | 2020 | Hepatitis B reactivation: diagnosis and management | SHANG-CHIN HUANG ; HUNG-CHIH YANG ; JIA-HORNG KAO | Expert Review of Gastroenterology and Hepatology | 18 | 15 | |
225 | 2017 | Hepatitis B reactivation in patients receiving immunosuppressive therapy: a hidden menace | Lin C.-L.; JIA-HORNG KAO | Hepatology International | 2 | 2 | |
226 | 2010 | Hepatitis B e antigen seroconversion: A critical event in chronic hepatitis B virus Infection | Liaw Y.-F.; Lau G.K.K.; JIA-HORNG KAO ; Gane E. | Digestive Diseases and Sciences | 85 | 74 | |
227 | 2018 | HCC risk in patients with HBV-related cirrhosis receiving nucleos(t)ide analogues therapy: Is HCC prevented or delayed? | TUNG-HUNG SU ; TAI-CHUNG TSENG ; JIA-HORNG KAO | Hepatology | 11 | 10 | |
228 | 2017 | HBV markers for HCC prediction: Three heads are better than two? | TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of Hepatology | 6 | 3 | |
229 | 2006 | HBV genotypes: Epidemiology and implications regarding natural history | JIA-HORNG KAO ; DING-SHINN CHEN | Current Hepatitis Reports | 30 | 0 | |
230 | 2005 | HBV genotypes and outcome of HBV infection [1] (multiple letters) | JIA-HORNG KAO ; DING-SHINN CHEN ; Lok A.S.F. | Hepatology | 7 | 6 | |
231 | 2009 | HBV genotypes and chronicification of acute hepatitis B: More questions than answers | Lin C.-L.; JIA-HORNG KAO | Gut | 1 | 0 | |
232 | 2008 | HBV Genotype and Clinical Outcome of Chronic Hepatitis B: Facts and Puzzles | TAI-CHUNG TSENG ; JIA-HORNG KAO | Gastroenterology | 17 | 16 | |
233 | 2009 | HBsAg Seroclearance: The More and Earlier, the Better | TAI-CHUNG TSENG ; JIA-HORNG KAO | Gastroenterology | 4 | 4 | |
234 | 2014 | HBeAg-positive chronic hepatitis B: Why do I treat my patients with pegylated interferon? | JIA-HORNG KAO | Liver International | 45 | 41 | |
235 | 2013 | Global perspective on the natural history of chronic hepatitis B: Role of hepatitis B virus genotypes A to J | CHUN-JEN LIU ; JIA-HORNG KAO | Seminars in Liver Disease | 141 | 125 | |
236 | 2022 | Global multi-stakeholder endorsement of the MAFLD definition | Méndez-Sánchez, Nahum; Bugianesi, Elisabetta; Gish, Robert G; Lammert, Frank; Tilg, Herbert; Nguyen, Mindie H; Sarin, Shiv K; Fabrellas, Núria; Zelber-Sagi, Shira; Fan, Jian-Gao; Shiha, Gamal; Targher, Giovanni; Zheng, Ming-Hua; Chan, Wah-Kheong; Vinker, Shlomo; Kawaguchi, Takumi; Castera, Laurent; Yilmaz, Yusuf; Korenjak, Marko; Spearman, C Wendy; Ungan, Mehmet; Palmer, Melissa; El-Shabrawi, Mortada; Gruss, Hans-Juergen; Dufour, Jean-François; Dhawan, Anil; Wedemeyer, Heiner; George, Jacob; Valenti, Luca; Fouad, Yasser; Romero-Gomez, Manuel; Eslam, Mohammed; JIA-HORNG KAO et al. | The lancet. Gastroenterology & hepatology | 139 | 123 | |
237 | 2002 | Global control of hepatitis B virus infection | JIA-HORNG KAO ; DING-SHINN CHEN | Lancet Infectious Diseases | 714 | 631 | |
238 | 2012 | Genomic variation-guided management in chronic hepatitis C | Hsu C.-S.; JIA-HORNG KAO | Expert Review of Gastroenterology and Hepatology | 9 | 9 | |
239 | 2008 | Genetic variability of hepatitis B virus and response to antiviral therapy | CHUN-JEN LIU ; JIA-HORNG KAO | Antiviral Therapy | 40 | 28 | |
240 | 1996 | GBV-C/HGV infection and aplastic anaemia [7] | JIA-HORNG KAO ; PEI-JER CHEN ; Lai M.-Y.; DING-SHINN CHEN | Lancet | 9 | 8 | |
241 | 1996 | GBV-C in the aetiology of fulminant hepatitis [6] | JIA-HORNG KAO ; PEI-JER CHEN ; DING-SHINN CHEN ; Mishiro S.; Yoshiba M.; Okamoto H. | Lancet | 83 | 87 | |
242 | 1999 | GB virus-C/hepatitis G virus infection in Taiwan: A virus that fails to cause a disease? | JIA-HORNG KAO ; DING-SHINN CHEN | Journal of Biomedical Science | 15 | 0 | |
243 | 2023 | Gamma-glutamyl transferase levels in the prediction of the outcomes of hepatocellular carcinoma after surgical resection | TUNG-HUNG SU ; JIA-HORNG KAO | Journal of the Formosan Medical Association = Taiwan yi zhi | 0 | 0 | |
244 | 2010 | From liver markers to life expectancy | Wang C.-C.; JIA-HORNG KAO | Hepatology | 0 | 0 | |
245 | 2013 | Fluvastatin helps interferon-based therapy in chronic hepatitis C: Fact or fiction? | Hsu C.-S.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 2 | 1 | |
246 | 2024 | Expert consensus on the diagnosis and treatment of end-stage liver disease complicated by infections | Chen, Tao; Chen, Guang; Wang, Guiqiang; Treeprasertsuk, Sombat; Lesmana, Cosmas Rinaldi Adithya; Lin, Han-Chieh; Al-Mahtab, Mamun; Chawla, Yogesh K; Tan, Soek-Siam; JIA-HORNG KAO ; Yuen, Man-Fung; Lee, Guan-Huei; Alcantara-Payawal, Diana; Nakayama, Nobuaki; Abbas, Zaigham; Jafri, Wasim; Kim, Dong-Joon; Choudhury, Ashok; Mahiwall, Rakhi; Hou, Jinlin; Hamid, Saeed; Jia, Jidong; Bajaj, J S; Wang, Fusheng; Sarin, Shiv K; Ning, Qin | Hepatology international | |||
247 | 2013 | Evolution of viral biomarkers in predicting outcomes of chronic hepatitis B patients: From DNA to surface antigen | TAI-CHUNG TSENG ; JIA-HORNG KAO | Tzu Chi Medical Journal | 3 | 0 | |
248 | 2023 | Evidence for Benefits of Early Treatment Initiation for Chronic Hepatitis B | Lim, Young Suk; Kim, W. Ray; Dieterich, Douglas; JIA-HORNG KAO ; Flaherty, John F.; Yee, Leland J.; Roberts, Lewis R.; Razavi, Homie; Kennedy, Patrick T.F. | Viruses | 4 | 1 | |
249 | 2009 | Esomeprazole for asthma [7] | Hsu C.-S.; JIA-HORNG KAO | New England Journal of Medicine | 1 | 2 | |
250 | 2012 | Erratum: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2012 update (Hepatology International (2012) 6 (531-561) DOI: 10.1007/s12072-012-9365-4) | Liaw Y.-F.; JIA-HORNG KAO ; Piratvisuth T.; Chan H.L.Y.; Chien R.-N.; CHUN-JEN LIU ; Gane E.; Locarnini S.; Lim S.-G.; Han K.-H.; Amarapurkar D.; Cooksley G.; Jafri W.; Mohamed R.; Hou J.-L.; Chuang W.-L.; Lesmana L.A.; Sollano J.D.; Suh D.-J.; Omata M. | Hepatology International | 16 | 18 | |
251 | 2008 | Erratum: Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update (Hepatology International 10.1007/s12072-008-9080-3) | Liaw Y.-F.; Leung N.; JIA-HORNG KAO ; Teerha P.; Gane E.; Han K.-H.; Guan R.; Lau G.K.K.; Locarnini S. | Hepatology International | 0 | 0 | |
252 | 2023 | Erratum to 'Impact of HBV infection on clinical outcomes in patients with metabolic dysfunction-associated fatty liver disease' (JHEP Reports 5 [2023] 100836) | Cheng, Yu-Ming; Hsieh, Tsung-Han; Wang, Chia-Chi; JIA-HORNG KAO | JHEP reports : innovation in hepatology | 0 | ||
253 | 2011 | Entecavir: A review of its use in the treatment of chronic hepatitis B in patients with decompensated liver disease | Keating G.M.; Buti M.; Gadano A.; JIA-HORNG KAO ; Lee C.-M.; Peng C.-Y.; Schiff E.R.; Tanwandee T. | Drugs | 21 | 18 | |
254 | 2017 | Elimination of Hepatitis B: Is It a Mission Possible? | TAI-CHUNG TSENG ; JIA-HORNG KAO | BMC Medicine | 29 | 27 | |
255 | 2005 | Effects of diabetes on the ED presentation of acute intermittent porphyria [3] | Chen H.-W.; Su D.-H.; TZUU-SHUH JOU ; JIA-HORNG KAO | American Journal of Emergency Medicine | 0 | 0 | |
256 | 2019 | Editorial: nephrotoxicity and oral anti-viral therapy for HBV-facts or fiction? | CHEN-HUA LIU ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 1 | 1 | |
257 | 2020 | Editorial: increasing burden of nonalcoholic fatty liver disease—a call to action. Authors' reply | Estes C.; Chan H.L.Y.; Chien R.N.; Chuang W.-L.; Fung J.; Goh G.B.-B.; Hu T.H.; Huang J.-F.; Jang B.K.; Jun D.W.; JIA-HORNG KAO ; Lee J.-W.; Lin H.-C.; Razavi-Shearer K.; Seto W.-K.; Wong G.L.H.; Wong V.W.S.; Razavi H. | Alimentary Pharmacology and Therapeutics | 1 | 0 | |
258 | 2019 | Editorial: comorbidities, concomitant medications and potential drug-drug interactions with interferon-free direct-acting anti-viral agents in chronic hepatitis C – authors’ reply | CHEN-HUA LIU ; JIA-HORNG KAO | Alimentary Pharmacology and Therapeutics | 0 | 0 | |
259 | 2020 | East Asia expert opinion on treatment initiation for chronic hepatitis B | JIA-HORNG KAO ; Hu T.-H.; Jia J.; Kurosaki M.; Lim Y.-S.; Lin H.-C.; Sinn D.H.; Tanaka Y.; Wai-Sun Wong V.; Yuen M.-F. | Alimentary Pharmacology and Therapeutics | 42 | 32 | |
260 | 2012 | Dynamic contrast-enhanced magnetic resonance imaging with Gd-EOB-DTPA for the evaluation of liver fibrosis in chronic hepatitis patients | BANG-BIN CHEN ; CHAO-YU HSU ; CHIH-WEI YU ; Wei S.-Y.; JIA-HORNG KAO ; Lee, Hsuan-Shu ; TIFFANY TING-FANG SHIH | European Radiology | 98 | 83 | |
261 | 2008 | Diagnosis of hepatitis B virus infection through serological and virological markers | JIA-HORNG KAO | Expert Review of Gastroenterology and Hepatology | 106 | 0 | |
262 | 2016 | Daclatasvir-containing all-oral regimens for the treatment of hepatitis C virus infection | Yang S.-S.; JIA-HORNG KAO | Hepatology International | 8 | 8 | |
263 | 2008 | Critical analysis of the immune tolerance phase of chronic HBV infection: Natural history and diagnosis | JIA-HORNG KAO ; DING-SHINN CHEN | Current Hepatitis Reports | 4 | 0 | |
264 | 2023 | Correction: Diversity and composition of gut microbiota in healthy individuals and patients at different stages of hepatitis B virus-related liver disease | Lin, Meng-Ju; TUNG-HUNG SU ; CHIEH-CHANG CHEN ; WEI-KAI WU ; SHIH-JER HSU ; TAI-CHUNG TSENG ; SIH-HAN LIAO ; CHUN-MING HONG ; HUNG-CHIH YANG ; CHUN-JEN LIU ; MING-SHIANG WU ; JIA-HORNG KAO | Gut pathogens | 0 | 0 | |
265 | 2021 | Correction to: Combined viral quasispecies diversity and hepatitis B core-related antigen predict off-nucleos(t)ide analog durability in HBeAg-negative patients | Cheng, Huei-Ru; HUNG-CHIH YANG ; Lin, Su-Ru; Yang, Ta-Yu; Lin, You-Yu; TUNG-HUNG SU ; TAI-CHUNG TSENG ; CHUN-JEN LIU ; JIA-HORNG KAO | Hepatology international | 0 | 0 | |
266 | 2008 | Core promoter mutations of hepatitis B virus and hepatocellular carcinoma: Story beyond A1762T/G1764A mutations | CHUN-JEN LIU ; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 5 | 5 | |
267 | 2008 | Combination of Hepatitis B Viral Factors and Advanced Liver Disease in HBeAg-Negative Patients: The More, the Worse? | Lin C.; Branch R.; JIA-HORNG KAO | Gastroenterology | 0 | 0 | |
268 | 2013 | Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: New trick of old dog | TAI-CHUNG TSENG ; JIA-HORNG KAO | Journal of Gastroenterology | 103 | 94 | |
269 | 2006 | Clinical significance of occult hepatitis B virus infection cannot be overlooked [11] | CHUN-JEN LIU ; JIA-HORNG KAO ; DING-SHINN CHEN | Clinical Infectious Diseases | 1 | 1 | |
270 | 2003 | Clinical Relevance of Hepatitis B Virus Genotypes Ba and Bj in Taiwan [6] (multiple letters) | JIA-HORNG KAO ; DING-SHINN CHEN ; Sugauchi F.; Miyakawa Y.; Mizokami M. | Gastroenterology | 18 | 14 | |
271 | 2002 | Clinical relevance of hepatitis B viral genotypes: a case of déjà vu? | JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 17 | 16 | |
272 | 2020 | The clinical manifestations and management of COVID-19-related liver injury | TUNG-HUNG SU ; JIA-HORNG KAO | Journal of the Formosan Medical Association | 31 | 25 | |
273 | 2011 | The clinical implications of hepatitis B virus genotype: Recent advances | Lin C.-L.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 296 | 266 | |
274 | 2005 | Changing disease burden of hepatocellular carcinoma in the Far East and Southeast Asia | JIA-HORNG KAO ; DING-SHINN CHEN | Liver International | 100 | 88 | |
275 | 2010 | Carvedilol versus variceal band ligation for prevention of the first variceal bleed | Wang C.-C.; JIA-HORNG KAO | Hepatology | 0 | 0 | |
276 | 2009 | Capsule endoscopy versus colonoscopy | Hsu C.-S.; JIA-HORNG KAO | New England Journal of Medicine | 0 | ||
277 | 2015 | Can noninvasive biomarkers replace liver biopsy for chronic hepatitis B? | Lin C.-L.; JIA-HORNG KAO | Hepatology (Baltimore, Md.) | 1 | 1 | |
278 | 2009 | Both insulin resistance and alanine aminotransferase level increase the risks of cardiovascular disease in fatty liver disease | Hsu C.-S.; DING-SHINN CHEN ; JIA-HORNG KAO | Hepatology | 0 | 0 | |
279 | 1997 | Blood-bank screening for hepatitis G [14] | JIA-HORNG KAO ; PEI-JER CHEN ; JIN-TOWN WANG ; Lai M.-Y.; DING-SHINN CHEN | Lancet | 7 | 5 | |
280 | 2017 | Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B | Wei L.; JIA-HORNG KAO | Current Medical Research and Opinion | 14 | 12 | |
281 | 2008 | Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2008 update | Liaw Y.-F.; Leung N.; JIA-HORNG KAO ; Piratvisuth T.; Gane E.; Han K.-H.; Guan R.; Lau G.K.K.; Locarnini S. | Hepatology International | 836 | 748 | |
282 | 2005 | Asian-Pacific consensus statement on the management of chronic hepatitis B: A 2005 update | Liaw Y.-F.; Leung N.; Guan R.; Lau G.K.K.; Merican I.; McCaughan G.; Gane E.; JIA-HORNG KAO ; Omata M.; Chutaputti B.A.; DING-SHINN CHEN ; Chien R.N.; Cooksley G.; Han K.H.; Ichida T.; Lai M.Y.; Lesmana L.; Piratvisuth T.; Sarin S.K.; Sollano J.; Suh D.J.; Yao G.B.; Yeh C.T.; Yokosuka O. | Liver International | 334 | 271 | |
283 | 2016 | Asian-Pacific clinical practice guidelines on the management of hepatitis B: a 2015 update | Sarin S.K.; Kumar M.; Lau G.K.; Abbas Z.; Chan H.L.Y.; Chen C.J.; DING-SHINN CHEN ; HUEY-LING CHEN ; PEI-JER CHEN ; Chien R.N.; Dokmeci A.K.; Gane E.; Hou J.L.; Jafri W.; Jia J.; Kim J.H.; Lai C.L.; Lee H.C.; Lim S.G.; CHUN-JEN LIU ; Locarnini S.; Al Mahtab M.; Mohamed R.; Omata M.; Park J.; Piratvisuth T.; Sharma B.C.; Sollano J.; Wang F.S.; Wei L.; Yuen M.F.; Zheng S.S.; JIA-HORNG KAO | Hepatology International | 1819 | 1662 | |
284 | 2020 | The Asian Pacific Association for the Study of the Liver clinical practice guidelines for the diagnosis and management of metabolic associated fatty liver disease | Eslam M.; Sarin S.K.; Wong V.W.-S.; Fan J.-G.; Kawaguchi T.; Ahn S.H.; Zheng M.-H.; Shiha G.; Yilmaz Y.; Gani R.; Alam S.; Dan Y.Y.; JIA-HORNG KAO ; Hamid S.; Cua I.H.; Chan W.-K.; Payawal D.; Tan S.-S.; Tanwandee T.; Adams L.A.; Kumar M.; Omata M.; George J. | Hepatology International | 393 | 339 | |
285 | 2015 | Artificial ascites is feasible and effective for difficult-to-ablate hepatocellular carcinoma | Wang C.-C.; JIA-HORNG KAO | Hepatology International | 27 | 27 | |
286 | 2007 | APRI-M6 for predicting long-term outcome of chronic hepatitis C patients after interferon-based therapy: More questions than answers [5] | TUNG-HUNG SU ; JIA-HORNG KAO ; DING-SHINN CHEN | Hepatology | 0 | 0 | |
287 | 2016 | APASL consensus statements and recommendations for hepatitis C prevention, epidemiology, and laboratory testing | Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Al-Mahtab M.; McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO ; Yokosuka O.; Lau G.K.K.; Sarin S.K. | Hepatology International | 72 | 70 | |
288 | 2016 | APASL consensus statements and recommendation on treatment of hepatitis C | Omata M.; Kanda T.; Wei L.; Yu M.-L.; Chuang W.-L.; Ibrahim A.; Lesmana C.R.A.; Sollano J.; Kumar M.; Jindal A.; Sharma B.C.; Hamid S.S.; Dokmeci A.K.; Mamun-Al-Mahtab, McCaughan G.W.; Wasim J.; Crawford D.H.G.; JIA-HORNG KAO ; Yokosuka O.; Lau G.K.K.; Sarin S.K. | Hepatology International | 185 | 167 | |
289 | 2022 | APASL clinical practice guidance: the diagnosis and management of patients with primary biliary cholangitis | You H.; Ma X.; Efe C.; Wang G.; Jeong S.-H.; Abe K.; Duan W.; Chen S.; Kong Y.; Zhang D.; Wei L.; Wang F.-S.; Lin H.-C.; Yang J.M.; Tanwandee T.; Gani R.A.; Payawal D.A.; Sharma B.C.; Hou J.; Yokosuka O.; Dokmeci A.K.; Crawford D.; JIA-HORNG KAO ; Piratvisuth T.; Suh D.J.; Lesmana L.A.; Sollano J.; Lau G.; Sarin S.K.; Omata M.; Tanaka A.; Jia J. | Hepatology International | 35 | 19 | |
290 | 2023 | Anti-HBc level predicting virological relapse after stopping nucleos(t)ide analogue in chronic hepatitis B | Huang, Chiuan-Bo; TUNG-HUNG SU ; JIA-HORNG KAO | Liver international : official journal of the International Association for the Study of the Liver | 1 | 1 | |
291 | 2011 | Alpha-fetoprotein in chronic hepatitis C | Hsu C.-S.; JIA-HORNG KAO | Journal of the Formosan Medical Association | 0 | 0 | |
292 | 2010 | Alanine aminotransferase, metabolic syndrome, and cardiovascular disease: A missing link | Wang C.-C.; JIA-HORNG KAO | American Journal of Gastroenterology | 3 | 2 | |
293 | 2022 | Advancing the global public health agenda for NAFLD: a consensus statement | Lazarus J.V.; Mark H.E.; Anstee Q.M.; Arab J.P.; Batterham R.L.; Castera L.; Cortez-Pinto H.; Crespo J.; Cusi K.; Dirac M.A.; Francque S.; Hickman I.J.; Hocking S.L.; Hunyady B.; Idilman R.; Isakov V.A.; Jamal M.H.; Jepsen P.; Iskandar N.J.; Song M.J.; Sudhamshu K.C.; George J.; Kakizaki S.; Kalamitsis G.; Kanwal F.; JIA-HORNG KAO ; Kaplan L.; Kawaguchi T.; Khader Y.; Kim S.U.; Kodjoh N.; Koek G.; Hagström H.; Koike K.; Komas N.P.; Korenjak M.; Kugelmas M.; Labidi A.; Lange N.F.; Lavine J.E.; Lazo M.; Lee N.; Lesmana C.R.A.; Huang T.T.-K.; CHUN-JEN LIU ; Long M.T.; Lopez-Jaramillo P.; Malekzadeh R.; Mahtab M.A.; Marchesini G.; Marinho R.; Vázquez S.E.M.; Mateva L.; Nlombi C.M.; Ismail M.H.; Melin P.; Mikolasevic I.; Milovanovic T.; Musso C.; Nakajima A.; Nava E.; Nersesov A.V.; Nikolova D.; Norris S.; Novak K.; Kautz A.; Oben J.; Ong J.P.; Onyekwere C.; Papatheodoridis G.; Paruk I.; Patel K.; Macedo M.P.; Penha-Gonçalves C.; Figueroa M.P.; Hofmann W.P.; Sarin S.K.; Petta S.; de Oliveira C.P.M.S.; Puri P.; Pan C.Q.; Rac M.; Ralston J.; Ramji A.; Razavi H.; Alvares-da-Silva M.R.; Roberts S.; Loomba R.; Roden M.; Rose T.; Rouabhia S.; Rovere-Querini P.; Rowe I.A.; Sadirova S.; Salupere R.; Saparbu T.; Sayegh R.; Sebastiani G.; Miller V.; Seki Y.; Selmo J.; Serme A.K.; Shaw J.E.; Shenoy T.; Sheron N.; Shibolet O.; Silva M.; Skrypnyk I.; Socha P.; Newsome P.N.; Soriano J.; Spearman C.W.; Sridharan K.; Suárez J.J.; Sheriff D.S.; Sung K.-C.; Swain M.; Tacke F.; Taheri S.; Tan S.-S.; Ninburg M.; Tapper E.B.; Yki-Järvinen H.; Thiele M.; Shawa I.T.; Tolmane I.; Torres E.A.; Trauner M.; Treeprasertsuk S.; Turcanu A.; Valantinas J.; Ocama P.; Vesterhus M.; Waked I.; Wild S.H.; Willemse J.; Wong R.J.; Xanthakos S.; Young D.Y.; Yu M.-L.; Zheng K.I.; Zeybel M.; Ratziu V.; Zheng M.-H.; the NAFLD Consensus Consortium; Rinella M.; Romero D.; Romero-Gómez M.; Schattenberg J.M.; Tsochatzis E.A.; Valenti L.; Wong V.W.-S.; Yilmaz Y.; Younossi Z.M.; Zelber-Sagi S.; Åberg F.; Adams L.; Khatry M.S.A.; Naamani K.A.; Murillo O.A.; Allen A.M.; Alnaser F.; Alqahtani S.A.; Alswat K.; Alvaro D.; Andrade R.J.; Arrese M.; Awuku Y.A.; Ayesha M.; Baatarkhuu O.; Bakieva S.; Basu R.; Bataller R.; Bedri S.; Bosi E.; Bourliere M.; Bruha R.; Bugianesi E.; Burra P.; Buti M.; Byrne C.D.; Calleja J.L.; Carrieri P.; Carter F.; Fernandez M.I.C.; Castillo-Lopez G.; Castro-Narro G.E.; Chan H.L.Y.; Chan W.-K.; Chang Y.; Colombo M.; Coppell K.J.; Corey K.; Craxi A.; Cryer D.; Dassanayake A.; Martins A.A.S.; de Ledinghen V.; DelPrato S.; Demaio A.; Desalegn H.; Dillon J.; Duseja A.; Dorairaj P.; Ekstedt M.; El Kassas M.; Elsanousi O.M.; Esmat G.; Fan J.-G.; Farpour-Lambert N.; Flisiak R.; Fouad Y.; Fuchs M.; Gani R.A.; Gerber L.; Ghazinyan H.; Gheorghe L.; Goh G.B.-B.; Grønbæk H.; Gulnara A.; Hamid S.; Hebditch V. | Nature Reviews Gastroenterology and Hepatology | 328 | 283 | |
294 | 2012 | Advances in the treatment of chronic hepatitis C: From interferon to direct acting anti-virals | CHUN-JEN LIU ; Hsu C.-S.; JIA-HORNG KAO | Journal of Internal Medicine of Taiwan | 1 | ||
295 | 2008 | Acute fatty liver of pregnancy with concurrent acute hepatitis B virus infection | TUNG-HUNG SU ; CHUN-JEN LIU ; PEI-JER CHEN ; DING-SHINN CHEN ; JIA-HORNG KAO | American Journal of Gastroenterology | 0 | 0 |